Pusic I, Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host disease after failure of frontline corticosteroids: results of a multicenter open-label phase 2-study. EHA 2017, S492.
Ibrutinib-venetoclax bij CLL leidt vaker tot niet-detecteerbare MRD
sep 2025 | Leukemie